Search Results - "Jacene, H."

Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer by Leboulleux, S., Schroeder, P. R., Busaidy, N. L., Auperin, A., Corone, C., Jacene, H. A., Ewertz, M. E., Bournaud, C., Wahl, R. L., Sherman, S. I., Ladenson, P. W., Schlumberger, M.

“…Purpose: The purpose of the study was to assess prospectively the impact of recombinant human TSH (rhTSH) administration on positron emission tomography…”
Get full text

Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors by Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., Bushnell, D., O'Dorisio, T. M., Baum, R. P., Kulkarni, H. R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., Benson, A., Srirajaskanthan, R., Pavel, M., Mora, J., Berlin, J., Grande, E., Reed, N., Seregni, E., Öberg, Kjell, Sierra, M. Lopera, Santoro, P., Thevenet, T., Erion, J. L., Ruszniewski, P., Kwekkeboom, D., Krenning, E.

“…BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited…”
Get full text

1198P Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings by Strosberg, J., Ulaner, G., Halperin, D., Mehr, S.H., Li, D., Soares, H.P., Anthony, L.B., Kotiah, S., Jacene, H., Kunz, P.L., Ferreira, D., Li, J., Ma, K., Rearden, J., Moran, S., Hope, T., Singh, S., Morris, M.

Get full text

Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice by Jacene, Heather A, Filice, Ross, Kasecamp, Wayne, Wahl, Richard L

“…We retrospectively evaluated our single-center clinical experience with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab for therapy of refractory…”
Get full text

Pazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm) by Bossé, D., McKay, R.R., Gray, K.P., Michaelson, M.D., Sleeper, C., Walsh, M., Krajewski, K.M., Jacene, H., Bellmunt, J., Pomerantz, M.M., Harshman, L.C., Choueiri, T.K.

Get full text

Abstract OT1-01-07: A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer by Overmoyer, B, Goel, S, Regan, M, Hirshfield-Bartek, J, Schlosnagel, E, Yeh, E, Qin, L, Bellon, J, Nakhlis, F, Jacene, H, Winer, E

“…Abstract Background: HER2 negative(neg) inflammatory breast cancer(IBC) exhibits relative resistance to chemotherapy evidenced by pCR(pathologic complete…”
Get full text

Abstract P4-02-08: MRI changes in breast skin following preoperative therapy for inflammatory breast cancer (IBC) by Yeh, E, Rives, A, Guo, H, Regan, M, Birdwell, R, Nakhlis, F, Bellon, J, Warren, L, Hirshfield-Bartek, J, Jacene, H, Dominici, L, Overmoyer, B

“…Abstract Purpose: Standard treatment for IBC includes preoperative systemic therapy (PST), followed by mastectomy (M) and adjuvant radiation (R). Determining…”
Get full text

Abstract P6-18-03: Tumor profiling of inflammatory breast cancer: Advancing the tools needed for precision medicine by Hazra, A, Warren, L, Nakhlis, F, Bellon, JR, Hirshfield-Bartek, J, Jacene, H, Yeh, ED, Dominici, L, Schlosnagle, E, Hirko, K, Overmoyer, B

“…Abstract Introduction: Inflammatory breast cancer (IBC) is a rare and highly lethal form of breast cancer, accounting for approximately 10% of breast cancer…”
Get full text

2-Deoxy-2-[18F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers by Jacene, Heather A, Patel, Pavni P, Chin, Bennett B

“…The purpose of this study was to determine the frequency of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake in the intercostal respiratory muscles (ICM) of…”
Get more information

Abstract P5-02-01: Discrepancy between CT and FDG-PET/CT in the staging of patients with inflammatory breast cancer: Implications for radiation therapy treatment planning by Jacene, H, DiPiro, P, Bellon, J, Nakhlis, F, Hirshfield-Bartek, J, Yeh, E, Overmoyer, B

“…Abstract Background: To compare suspected areas of cancer involvement based on the findings of CT and FDG-PET/CT in patients with inflammatory breast cancer…”
Get full text

Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning-Monte Carlo Simulation Studies by He, Bin, Wahl, Richard L., Du, Yong, Sgouros, George, Jacene, Heather, Flinn, Ian, Frey, Eric C.

“…Estimating the residence times in tumor and normal organs is an essential part of treatment planning for radioimmunotherapy (RIT). This estimation is usually…”
Get full text

Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL) by Kasamon, Y. L., Jacene, H. A., Swinnen, L. J., Popplewell, L., Link, B. K., Habermann, T. M., Herman, J. M., Jones, R. J., Ambinder, R. F.

“…Abstract only…”
Get full text

Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment PlanningaMonte Carlo Simulation Studies by He, Bin, Wahl, R L, Du, Yong, Sgouros, G, Jacene, H, Flinn, I, Frey, E C

“…Estimating the residence times in tumor and normal organs is an essential part of treatment planning for radioimmunotherapy (RIT). This estimation is usually…”
Get full text

Changes in FDG-PET in response to rapamycin (R) correlated with Akt pathway inhibition and not with clinical outcome by Ma, W., Song, D., Jacene, H., Vilardell, F., Zhang, X., Messersmith, W., Endres, C., Jimeno, A., Pomper, M., Hidalgo, M.

“…Abstract only…”
Get full text

Phase I trial of yttrium 90 ibritumomab tiuxetan ( 90 Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) by Swinnen, L. J., Flinn, I. W., Kahl, B. S., Frey, E., Rogers, K., Jung, M., Jacene, H., Wahl, R. L.

“…Abstract only…”
Get full text

Abstract P6-09-10: Association of dermal lymphatic involvement and survival in inflammatory breast cancer by Hirko, KA, Schlossman, J, Harrison, BT, Yeh, ED, Jacene, HA, Nakhlis, F, Schlosnagle, E, Overmoyer, BA

“…Abstract Purpose: The pathologic hallmark of inflammatory breast cancer (IBC) is the presence of tumor emboli within the papillary and reticular dermis of the…”
Get full text

P-391 How dedicated Positron Emission Tomography-CT (PET-CT) affects the diagnostic and therapeutic approaches to patients managed by a Multimodality Thoracic Oncology Group by Yung, R., Gramatikova, A., Brock, M., Brahmer, J., Ettinger, D., Friedman, K., Jacene, H., Colvin, L., Lang, P., Yang, S.

Get full text

Abstract OT2-02-03: Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy by Jacene, HA, Overmoyer, B, Schlosnagle, EJ, Abbott, A, Yeh, E, Paolino, J, Goel, S, Culhane, A, Bellon, JR, Nakhlis, F, Hirshfield-Bartek, J, Van den Abbeele, A

“…Abstract Background: Inflammatory breast cancer (IBC) continues to have a poor prognosis despite standard tri-modality treatment with chemotherapy, mastectomy…”
Get full text

Abstract P6-18-02: Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer by Nakhlis, F, Regan, M, Chun, YS, Dominici, LS, Jacene, HA, Yeh, ED, Bellon, JR, Warren, LE, Hirko, K, Hirshfield-Bartek, J, Hazra, A, Overmoyer, BA

“…Abstract Background Inflammatory Breast Cancer (IBC) is a rare and aggressive type of breast cancer treated by multimodality therapy. Due to the presence of…”
Get full text

Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET by Subhas, Naveen, Patel, Pavni V, Pannu, Harpreet K, Jacene, Heather A, Fishman, Elliot K, Wahl, Richard L

“…The role of 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in combination with computed tomography (CT) in the evaluation of…”
Get full text